These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 28766366)

  • 21. DYRK1A: a potential drug target for multiple Down syndrome neuropathologies.
    Becker W; Soppa U; Tejedor FJ
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):26-33. PubMed ID: 24152332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.
    Zhou Q; Reekie TA; Abbassi RH; Indurthi Venkata D; Font JS; Ryan RM; Munoz L; Kassiou M
    Bioorg Med Chem; 2018 Dec; 26(22):5852-5869. PubMed ID: 30401502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule.
    Wu YW; HuangFu WC; Lin TE; Peng CH; Tu HJ; Sung TY; Sung TY; Yen SC; Pan SL; Hsu KC
    Int J Biol Macromol; 2024 Feb; 259(Pt 1):129074. PubMed ID: 38163507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
    Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System.
    Huizar FJ; Hill HM; Bacher EP; Eckert KE; Gulotty EM; Rodriguez KX; Tucker ZD; Banerjee M; Liu H; Wiest O; Zartman J; Ashfeld BL
    ChemMedChem; 2022 Feb; 17(4):e202100512. PubMed ID: 34994084
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Atas-Ozcan H; Brault V; Duchon A; Herault Y
    Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design.
    Meine R; Becker W; Falke H; Preu L; Loaëc N; Meijer L; Kunick C
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29364148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ.
    Sonamoto R; Kii I; Koike Y; Sumida Y; Kato-Sumida T; Okuno Y; Hosoya T; Hagiwara M
    Sci Rep; 2015 Aug; 5():12728. PubMed ID: 26234946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, Synthesis, and In Vitro Biological Activities of a Bio-Oxidizable Prodrug to Deliver Both ChEs and DYRK1A Inhibitors for AD Therapy.
    Barré A; Azzouz R; Gembus V; Papamicaël C; Levacher V
    Molecules; 2019 Apr; 24(7):. PubMed ID: 30939771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of potent small molecule inhibitors of DYRK1A by structure-based virtual screening and bioassay.
    Wang D; Wang F; Tan Y; Dong L; Chen L; Zhu W; Wang H
    Bioorg Med Chem Lett; 2012 Jan; 22(1):168-71. PubMed ID: 22154664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.
    Darwish SS; Abdel-Halim M; ElHady AK; Salah M; Abadi AH; Becker W; Engel M
    Eur J Med Chem; 2018 Oct; 158():270-285. PubMed ID: 30223116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation, regulation, and inhibition of DYRK1A.
    Becker W; Sippl W
    FEBS J; 2011 Jan; 278(2):246-56. PubMed ID: 21126318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer's Disease.
    Warren HT; Saeger HN; Tombari RJ; Chytil M; Rasmussen K; Olson DE
    J Med Chem; 2024 May; 67(9):6922-6937. PubMed ID: 38648167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation.
    Qiu N; Qian C; Guo T; Wang Y; Jin H; Yao M; Li M; Guo T; Lv Y; Si X; Wu S; Wang H; Zhang X; Xia J
    Int J Biol Macromol; 2024 Jun; 269(Pt 1):132024. PubMed ID: 38704072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study.
    Llorach-Pares L; Nonell-Canals A; Avila C; Sanchez-Martinez M
    Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30332805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-step virtual screening to develop selective DYRK1A inhibitors.
    Koyama T; Yamaotsu N; Nakagome I; Ozawa SI; Yoshida T; Hayakawa D; Hirono S
    J Mol Graph Model; 2017 Mar; 72():229-239. PubMed ID: 28129593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer's Disease.
    Chen H; Gao X; Li X; Yu C; Liu W; Qiu J; Liu W; Geng H; Zheng F; Gong H; Xu Z; Jia J; Zhao Q
    J Med Chem; 2024 Aug; 67(15):12571-12600. PubMed ID: 39041662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors.
    Pan Y; Wang Y; Bryant SH
    J Chem Inf Model; 2013 Apr; 53(4):938-47. PubMed ID: 23496085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hologram QSAR models of a series of 6-arylquinazolin-4-amine inhibitors of a new Alzheimer's disease target: dual specificity tyrosine-phosphorylation-regulated kinase-1A enzyme.
    Leal FD; da Silva Lima CH; de Alencastro RB; Castro HC; Rodrigues CR; Albuquerque MG
    Int J Mol Sci; 2015 Mar; 16(3):5235-53. PubMed ID: 25756379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
    Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
    Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.